Compare TASK & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | CABA |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.9M | 495.7M |
| IPO Year | 2021 | 2019 |
| Metric | TASK | CABA |
|---|---|---|
| Price | $5.08 | $3.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $14.70 | $14.50 |
| AVG Volume (30 Days) | 617.9K | ★ 5.6M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 10.26 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.95 | N/A |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $19.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.47 | $1.26 |
| 52 Week High | $18.39 | $4.23 |
| Indicator | TASK | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 51.38 |
| Support Level | $4.47 | $3.12 |
| Resistance Level | $6.62 | $3.34 |
| Average True Range (ATR) | 0.30 | 0.21 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 46.32 | 82.35 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.